Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 907 across all filing types
Latest filing 2024-08-25 Annual Report
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
FY24 Full Year Results 61 pages 3.3MB
Annual Report Classification · 95% confidence The document is titled 'APPENDIX 4E Preliminary Final Report' and is for Medical Developments International Limited for the year ended 30 June 2024. It contains detailed financial results, including revenue, net profit/loss, earnings per share, segment revenue, operating performance, cash flow, and balance sheet data. The document references the ASX listing rule 4.3C.2 and includes a statement that the audited Financial Report for the year ended 30 June 2024 is attached. The content includes comprehensive financial data and analysis for the full fiscal year, not just an announcement or summary. It is not a short announcement or a certification letter but a full financial report. Therefore, this document fits the definition of an Annual Report (10-K equivalent) as it covers the full year financial performance and detailed financial statements. FY 2024
2024-08-25 English
MVP Announces FY24 Full Year Results 4 pages 253.3KB
Annual Report Classification · 95% confidence The document is an ASX announcement dated 26 August 2024 presenting the full year financial results for FY24. It includes detailed financial performance metrics such as underlying EBIT, free cashflow, revenue growth, segment performance, and operational efficiencies. The text discusses the company's earnings, cashflow improvements, segment revenues, and outlook for FY25. It is a comprehensive financial report covering the full fiscal year ending 30 June 2024, with substantive financial data and management commentary on business trends and outlook. This matches the definition of an Annual Report (10-K) type document, as it is a full yearly report covering company activity and financial performance. The document length (9073 characters) and content confirm it is the report itself, not merely an announcement of a report publication or a brief earnings release. Therefore, the correct classification is Annual Report (10-K). FY 2024
2024-08-25 English
FY24 Full Year Results Investor Presentation 23 pages 5.3MB
Earnings Release Classification · 95% confidence The document is a detailed presentation of Medical Developments International Limited's full year financial results for FY24, dated 26 August 2024. It includes comprehensive financial performance data such as revenue, EBIT, cash flow, margins, strategic priorities, market penetration, and outlook for FY25. The content is typical of a full year financial results announcement, providing key messages, strategic highlights, growth drivers, and detailed segment performance. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or a simple notice. It is not a transcript, audit report, or regulatory filing. The presence of forward-looking statements, detailed financial metrics, and strategic commentary aligns with an Earnings Release (ER) document, which is the initial announcement of quarterly or periodical financial results with key highlights. Therefore, the document is best classified as an Earnings Release (ER). FY 2024
2024-08-25 English
Ceasing to be a substantial holder 10 pages 562.5KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 notice under the Corporations Act 2001 Section 671B, titled 'Notice of ceasing to be a substantial holder.' It details changes in substantial shareholding interests, including dates, nature of changes, and associated parties. It includes appendices with prescribed information about agreements related to voting rights and securities lending. The document is regulatory in nature, reporting changes in significant share ownership levels, which aligns with the definition of 'Major Shareholding Notification' (MRQ). The document length is over 10,000 characters and contains detailed data, not just an announcement or certification, confirming it is the substantive filing itself.
2024-08-15 English
FY24 Full Year Results Announcement Details 1 page
Report Publication Announcement Classification · 95% confidence The document is an announcement dated 15 August 2024 from Medical Developments International Ltd regarding the scheduled release of its full year financial results for the fiscal year ended 30 June 2024. It states the date of the results announcement (26 August 2024) and details about a webcast with the CEO and CFO. The document does not contain any actual financial data or detailed results, but rather informs investors about the upcoming release and webcast. The document length is short (1645 characters), and it serves as a notification rather than the report itself. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA) rather than the Annual Report (10-K) or Earnings Release (ER).
2024-08-14 English
Director's Interests - G. Naylor 2 pages 275.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares and options held before and after the change, nature of the interest, and dates. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document length is 3160 characters, which is consistent with a detailed notice of director's interest change rather than a full financial report or announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2024-08-11 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.